Neutropenia and Drug-Induced Agranulocytosis
Clinical Snapshot
Neutropenia is an absolute neutrophil count (ANC) under about 1.5 ×10⁹/L in adults; severity is graded mild, moderate, or severe, with agranulocytosis — ANC under 0.5 ×10⁹/L — carrying substantially higher infection risk, since neutrophils are the primary early defense against bacterial and fungal pathogens. Causes span chemotherapy-induced neutropenia (covered in the Infections in the Cancer Patient chapter, along with its febrile-neutropenia management and G-CSF prophylaxis), idiosyncratic drug-induced neutropenia/agranulocytosis from non-chemotherapy drugs — the focus of this chapter — autoimmune neutropenia, viral-associated transient neutropenia, and congenital/cyclic neutropenia syndromes. Idiosyncratic drug-induced agranulocytosis is rare but carries real mortality risk from sepsis if unrecognized, and pharmacists are frequently the first to catch it — through a mandatory monitoring program (clozapine) or by recognizing an early infective symptom in a patient recently started on a high-risk drug.[1]
Recognize the Condition
Neutropenia itself is often asymptomatic until infection develops — the presenting symptoms are usually those of infection (fever, mouth ulcers, sore throat, skin infection) rather than the low count itself, and a neutropenic patient cannot mount a normal inflammatory response, so exam findings (pus, a well-defined infiltrate) are often less impressive than the degree of infection actually present. Idiosyncratic drug-induced agranulocytosis typically has an abrupt onset, often within days to a few months of starting the causative drug — immune-mediated reactions can recur extremely fast (sometimes within hours) on re-exposure, while direct, dose-dependent marrow toxicity tends to develop more gradually.[1]
Severity tiers
Mild
ANC 1.0-1.5 ×10⁹/L. Minimal infection risk; observation alone is usually sufficient.
Moderate
ANC 0.5-1.0 ×10⁹/L. Infection risk is present but modest; stopping a causative drug is usually all that is needed.
Severe (agranulocytosis)
ANC under 0.5 ×10⁹/L. Substantial infection risk — any fever in this group is a medical emergency. Growth-factor support and hospitalization are considered here.
Distinguishing the common causes of unexpected neutropenia
| Feature | Idiosyncratic drug-induced | Chemotherapy-induced | Viral-associated (transient) | Autoimmune/chronic idiopathic |
|---|---|---|---|---|
| Onset | Abrupt, days to months after starting the causative drug | Predictable, within a defined post-cycle window | Acute, alongside or shortly after a viral illness | Gradual or longstanding |
| Severity | Often severe (agranulocytosis) | Dose- and regimen-dependent, often severe | Usually mild-moderate | Variable, often mild-moderate and stable |
| Course after removing the trigger | Recovery within 1-3 weeks of stopping the drug | Predictable nadir-and-recovery pattern each cycle | Self-limited, resolves within days to a couple of weeks | Chronic, persistent or fluctuating |
| Key clue | Temporal relationship to a new or dose-increased drug | Known myelosuppressive regimen and cycle timing | Concurrent or recent viral illness, usually in children | Other autoimmune features; antineutrophil antibodies where tested |
Risk Factors
- Exposure to a drug with recognized agranulocytosis risk — clozapine, antithyroid drugs (methimazole, propylthiouracil, carbimazole), sulfasalazine, ticlopidine, certain antibiotics (beta-lactams, trimethoprim-sulfamethoxazole), and some antiepileptics (carbamazepine).
- Older age (over 65).
- A higher starting dose or rapid dose escalation of a causative drug (for example, methimazole 30 mg versus 15 mg daily).
- Renal or hepatic impairment, reducing clearance of the causative drug.
- Concurrent bone-marrow-suppressing therapy.
- Underlying autoimmune disease, which increases the risk of immune-mediated neutropenia more broadly.
- Nutritional deficiency (vitamin B12, folate, copper) impairing neutrophil production.
- Recent viral infection — a common, usually self-limited, cause of transient neutropenia, particularly in children.
- Congenital or cyclic neutropenia syndromes (family history).
Red Flags & Refer
Escalate immediately for any of the following:
- Fever (a single reading of 38.3°C or higher, or 38.0°C or higher sustained for at least 1 hour) in a patient with a known or suspected ANC under 0.5 ×10⁹/L — a medical emergency requiring immediate assessment and empiric broad-spectrum antibiotics; do not wait for confirmatory labs before seeking care.
- Any sign of severe infection — hypotension, altered mental status, rigors — in a neutropenic patient; sepsis can progress extremely quickly with no neutrophils to contain it.
- ANC under 0.5 ×10⁹/L (agranulocytosis) discovered incidentally, even without fever — urgent assessment and immediate discontinuation of the suspected causative drug.
- Mucosal ulceration, a severe sore throat, or perianal pain in a patient on a known high-risk drug — a classic early presentation of agranulocytosis; evaluate immediately with a CBC.
- Any suspicion of a hematologic malignancy or marrow failure syndrome (other cytopenias, abnormal cells on the smear, unexplained bruising/bleeding alongside the neutropenia) — refer for bone marrow evaluation.
Assessment & Diagnosis
History
- Full medication history, including the start date of every new drug or dose change in the preceding weeks to months.
- Prior episodes, infection symptoms, autoimmune/rheumatologic history, recent viral illness, and family history.
Examination
Look specifically for signs of infection (oropharynx, skin, perianal region), and for lymphadenopathy or splenomegaly (which suggest an alternate cause) and signs of other cytopenias.
Laboratory evaluation
- CBC with differential and a peripheral smear — confirms the ANC and evaluates the other cell lines and morphology.
- When drug-induced agranulocytosis is suspected, the temporal relationship to the drug start is the key diagnostic clue — no specific confirmatory laboratory test exists. The diagnosis is clinical and temporal, supported by recovery after stopping the drug.[1]
- Blood cultures (peripheral and any line) before starting antibiotics if febrile.
- Bone marrow examination is not routinely needed for straightforward drug-induced agranulocytosis with a clear temporal relationship and expected recovery — reserve it for an atypical presentation, involvement of other cell lines, failure to recover after stopping the drug, or suspected malignancy/marrow failure.
- Rule out a lab-handling artifact if an isolated, unexpected finding lacks clinical correlation (uncommon, but less common than pseudothrombocytopenia is for platelets).
Treatment Targets
- Rapidly identify and stop the causative drug when the cause is drug-induced.
- Prevent, detect, and treat infection promptly.
- Support neutrophil recovery with G-CSF when clinically indicated.
- Avoid re-exposure to the causative drug, or a cross-reactive agent in the same class.
- Restore a normal ANC and avoid long-term sequelae.
Choose Initial Treatment
Any suspected drug-induced neutropenia or agranulocytosis — stop the suspected causative drug immediately; do not wait for laboratory or specialist confirmation before doing so.
Febrile or infected neutropenic patient — emergency assessment, blood cultures, and immediate empiric broad-spectrum IV antibiotics per local febrile-neutropenia protocol; see the Infections in the Cancer Patient chapter for the full antimicrobial selection framework, which applies to any neutropenic patient with fever, not only cancer patients.
Filgrastim (G-CSF) — reserve for severe (ANC under 0.5 ×10⁹/L) drug-induced agranulocytosis with infection or other high-risk features; growth-factor support can shorten neutrophil recovery time in idiosyncratic drug-induced agranulocytosis, though the evidence base is smaller than for chemotherapy-induced neutropenia.[2] It is not routinely needed for mild-to-moderate neutropenia or an asymptomatic patient, where stopping the causative drug alone is expected to lead to recovery within 1-3 weeks.
A patient on a known high-risk maintenance drug with mandatory hematologic monitoring (for example, clozapine) — follow that drug's specific monitoring-program action thresholds exactly rather than ad hoc clinical judgment; for clozapine specifically, follow the mandatory Canadian hematologic monitoring program's defined action levels for interruption, discontinuation, and rechallenge.
Non-Pharmacologic Treatment
- Neutropenic precautions during severe neutropenia: emphasize hand hygiene, avoid crowds and sick contacts, and use routine food-safety hygiene (avoid undercooked meat, unwashed produce, and unpasteurized products).
- Avoid elective invasive procedures (dental work, minor surgery) during severe neutropenia where they can reasonably be deferred.
- Maintain good oral hygiene with a soft toothbrush to reduce the risk of mucosal breach.
- Give clear instructions on prompt reporting of fever or infection symptoms, and when to present for urgent care.
- Do not rechallenge with the causative drug — permanent discontinuation is standard for immune-mediated agranulocytosis given the risk of a much faster, more severe recurrence on re-exposure.
Special Populations
Pregnancy
Mild physiologic neutropenia can occur in pregnancy. When neutropenia is drug-induced (for example, from an antithyroid drug used for Graves' disease), stopping or switching therapy requires balancing maternal thyroid control against agranulocytosis risk — this is a specialist-directed decision; propylthiouracil is generally preferred over methimazole specifically in the first trimester for teratogenicity reasons, not because of a materially different agranulocytosis risk between the two.[3] Filgrastim has been used in pregnancy for severe neutropenia when clearly clinically needed, with reassuring though limited data; it is not used electively.
Breastfeeding
Filgrastim is a large protein molecule with limited breastfeeding data; it is generally considered compatible with breastfeeding when clinically needed given expected minimal oral bioavailability to the infant. Antithyroid drugs (propylthiouracil and methimazole) are compatible with breastfeeding at usual doses.
Pediatrics
Benign, transient post-viral neutropenia is common in children and usually self-limited, needing no treatment. Drug-induced agranulocytosis is less common in children but can occur (for example, with antiepileptics). Autoimmune neutropenia of infancy is a distinct, usually benign, self-limited entity.
Clozapine-specific monitoring
Patients on clozapine require lifelong scheduled hematologic monitoring under the mandatory Canadian monitoring program. Follow the program's specific ANC action thresholds exactly for continuing, interrupting, or permanently discontinuing therapy — this is not a situation for ad hoc clinical judgment in place of the defined program rules, and monitoring frequency is highest in the first several months of treatment, when risk is greatest.
Renal/hepatic impairment
Dose-adjust the causative drug appropriately per its own monograph. Filgrastim does not require specific renal or hepatic dose adjustment, but use general caution in a critically unwell patient.
Monitoring & Follow-Up
Serial CBC with differential — daily during acute severe agranulocytosis or hospitalization, then per the recovery trend. Expect neutrophil recovery within 1-3 weeks after stopping the causative drug in most idiosyncratic cases; if recovery has not begun by then, reassess the diagnosis (consider marrow failure or an alternate cause) and consider bone marrow examination. Give clear temperature-monitoring and when-to-seek-care instructions for outpatient-managed mild-to-moderate cases. For high-risk maintenance drugs (clozapine, antithyroid drugs, sulfasalazine), follow the drug-specific mandatory or scheduled CBC monitoring protocol, especially during the first several months of therapy. Document the causative drug clearly in the patient's allergy/intolerance record and counsel that re-exposure is generally contraindicated for life.
Common Errors to Avoid
- Rechallenging a patient with the suspected causative drug "to confirm" the diagnosis — this risks a much faster, more severe recurrence in immune-mediated agranulocytosis and should essentially never be done deliberately.
- Switching to another drug in the same high-cross-reactivity class after antithyroid-drug agranulocytosis (for example, methimazole to propylthiouracil) without specialist input.
- Attributing fever in a neutropenic patient to a benign cause and delaying antibiotics while awaiting confirmatory cultures.
- Ordering a bone marrow examination reflexively for every case of drug-induced agranulocytosis with a clear temporal drug relationship and an expected recovery course.
- Missing a new high-risk drug start, or a recent dose increase, as the cause of new neutropenia found on routine bloodwork.
- Forgetting to document the causative drug and to counsel the patient and prescriber against future re-exposure.
- Assuming G-CSF is required for every case of drug-induced neutropenia rather than reserving it for severe or complicated presentations.
Clinical Decision Algorithm
Drug Tables
How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Antibiotic selection for febrile neutropenia and cycle-based G-CSF prophylaxis dosing for chemotherapy are covered in the companion Infections in the Cancer Patient chapter, not reproduced here. Select any drug name to open its complete Pharmasist Drug Database page.
Hematopoietic growth factors (G-CSF)
Reserved for severe drug-induced agranulocytosis with infection or other high-risk features, not routine mild-moderate neutropenia.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Filgrastim | Adults: 5 mcg/kg SC once daily until ANC recovers, per institutional protocol | Bone pain, headache, rare splenic rupture, rare ARDS | None significant | Continue until ANC recovery; monitor CBC regularly during use. |
| Pegfilgrastim | Adults: 6 mg SC once | Bone pain, injection-site reactions, rare splenic rupture | None significant | Long-acting, single-dose formulation — better suited to cycle-based chemotherapy prophylaxis (see Infections in the Cancer Patient) than to a single active agranulocytosis episode. |
Immune-mediated agranulocytosis adjuncts
Reserved for refractory antibody-mediated agranulocytosis despite drug cessation and G-CSF, under specialist direction — limited evidence base.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Immunoglobulin (human), IV | Adults: 1 g/kg IV once, may repeat | Headache, aseptic meningitis, renal dysfunction, thrombosis, hemolysis | Live vaccine response may be blunted for a period afterward | |
| Prednisone | Adults: 0.5-1 mg/kg/day PO | Hyperglycemia, insomnia, mood change | Additive hyperglycemia with other diabetogenic drugs | Short course; not standard for uncomplicated idiosyncratic drug-induced agranulocytosis. |
Drugs commonly implicated in idiosyncratic neutropenia/agranulocytosis
This list is not exhaustive — consider any recently started or dose-increased drug as a possible cause, and check the specific product monograph.
| Drug/class | Typical onset | Comments |
|---|---|---|
| Methimazole / Propylthiouracil (antithyroid drugs) | Usually within the first 3 months of therapy | Risk is dose-related for methimazole (higher with 30 mg/day than 15 mg/day). Cross-reactivity between the two agents is common — do not simply switch within class after agranulocytosis without specialist input. |
| Clozapine (atypical antipsychotic) | Highest risk in the first 6 months, though can occur later | Requires mandatory, scheduled hematologic monitoring for the duration of therapy under the Canadian monitoring program; follow its defined ANC action thresholds exactly. |
| Sulfasalazine (sulfonamide-related anti-inflammatory) | Usually within the first few months | Also causes other hematologic reactions (megaloblastic anemia via folate antagonism) — CBC monitoring is routine during initiation. |
| Ticlopidine (antiplatelet) | Usually within the first 3 months | A recognized high-risk agent historically; largely superseded by other antiplatelet agents with a lower hematologic risk profile. |
| Beta-lactam antibiotics; Sulfamethoxazole/Trimethoprim | Variable, days to weeks | Usually reversible on discontinuation; more common with prolonged high-dose courses. |
| Carbamazepine (antiepileptic) | Variable, weeks to months | Mild, transient leukopenia is common and does not usually require discontinuation; true agranulocytosis is rare but reportable. |
Evidence note: drug inventory, dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against current primary literature.[1]
References
- State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies — Journal of Clinical Medicine (Andrès E, Villalba NL, Zulfiqar AA, Serraj K, Mourot-Cottet R, Gottenberg JE). J Clin Med 2019;8(9):1351
- WBC Growth Factors: ASCO Guideline Update — Journal of Clinical Oncology, American Society of Clinical Oncology (Gyawali B, Bohlke K, Dickter JK, et al.). J Clin Oncol 2026;44(9):812-824
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis — Thyroid, American Thyroid Association (Ross DS, Burch HB, Cooper DS, et al.). Thyroid 2016;26(10):1343-1421
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.